Simplification to lopinavir/ritonavir monotherapy in HIV-infected children;Simplificación a monoterapia con lopinavir/ritonavir en niños infectados por el virus de la inmunodeficiencia humana

Anales de Pediatria

Volumn 75, Issue 1, 2011, Pages 51-54

  Mur Sierra, A ^a   Lopez Segura N ^a   Lopez Vilchez M A ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Children; Human immunodeficiency virus; Lopinavir ritonavir; Monotherapy

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; PEDIATRICS; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; CHILD; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; RETROSPECTIVE STUDIES; RITONAVIR;

EID: 79959380539     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2010.12.006     Document Type: Article

References (10)

1. W.F. Bierman, M.A. Van Agtmael, M. Nijhuis, S.A. Danner, and C.A. Boucher HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review AIDS. 23 2009 279 291
2. J.R. Arribas, A. Horban, J. Gerstoft, G. Fätkenheuer, M. Nelson, and N. Clumeck The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml AIDS. 24 2010 223 230
3. C. Katlama, M.A. Valantin, M. Algarte-Genin, C. Duvivier, S. Lambert-Niclot, and P.M. Girard Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136 AIDS. 24 2010 2365 2374
4. Bunupuradah T, Lumbiganon P, Puthanakit T, Ananworanich J, Mengthaisong T, Apornpong T, et al. Simplifying antiretroviral treatment in virally suppressed children by switching from double boosted protease inhibitors to lopinavir/ritonavir monotherapy [abstract MOPEB062]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22; Cape Town, South Africa.
5. J.R. Arribas, R. Delgado, A. Arranz, R. Muñoz, J. Portilla, and J. Pasquau Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis J Acquir Immune Defic Syndr. 51 2009 147 152
6. I. Perez Valero Factores pronósticos de respuesta virológica en pacientes tratados con lopinavir potenciado con ritonavir en monoterapia Enferm Infecc Microbiol Clin. 26 2008 27 33
7. C. Gutmann, A. Cusini, H.F. Günthard, C. Fux, B. Hirschel, and L.A. Decosterd Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir AIDS. 24 2010 2347 2354
8. D.W. Cameron, B.A. Da Silva, J.R. Arribas, R.A. Myers, N.C. Bellos, and N. Gilmore A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy J Infect Dis. 198 2008 234 240 (Pubitemid 352019289)
9. P. De Truchis, D. Mathez, E. Abe, A. Dinh, D. Ledu, and A. Greder-Belan Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy AIDS. 24 2010 1235 1236
10. M. Penazzato, D. Don, P.S. Wool, O. Rampon, and C. Giaquinto Update on antiretroviral therapy in paediatrics Antiviral Res. 85 2010 266 275